» Articles » PMID: 38852020

DCRM 2.0: Multispecialty Practice Recommendations for the Management of Diabetes, Cardiorenal, and Metabolic Diseases

Abstract

The spectrum of cardiorenal and metabolic diseases comprises many disorders, including obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), dyslipidemias, hypertension, and associated comorbidities such as pulmonary diseases and metabolism dysfunction-associated steatotic liver disease and metabolism dysfunction-associated steatohepatitis (MASLD and MASH, respectively, formerly known as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis [NAFLD and NASH]). Because cardiorenal and metabolic diseases share pathophysiologic pathways, two or more are often present in the same individual. Findings from recent outcome trials have demonstrated benefits of various treatments across a range of conditions, suggesting a need for practice recommendations that will guide clinicians to better manage complex conditions involving diabetes, cardiorenal, and/or metabolic (DCRM) diseases. To meet this need, we formed an international volunteer task force comprising leading cardiologists, nephrologists, endocrinologists, and primary care physicians to develop the DCRM 2.0 Practice Recommendations, an updated and expanded revision of a previously published multispecialty consensus on the comprehensive management of persons living with DCRM. The recommendations are presented as 22 separate graphics covering the essentials of management to improve general health, control cardiorenal risk factors, and manage cardiorenal and metabolic comorbidities, leading to improved patient outcomes.

Citing Articles

A multi-modal fusion model with enhanced feature representation for chronic kidney disease progression prediction.

Qiao Y, Zhou H, Liu Y, Chen R, Zhang X, Nie S Brief Bioinform. 2025; 26(1).

PMID: 39913621 PMC: 11801269. DOI: 10.1093/bib/bbaf003.


Epidemiological characteristics, complications of haemodialysis patients with end-stage diabetic nephropathy in a tertiary hospital in Guizhou, China: a cross-sectional survey.

Xu X, Yang N, Da J, Li Q, Yuan J, Zha Y Front Med (Lausanne). 2024; 11:1418075.

PMID: 39493712 PMC: 11527689. DOI: 10.3389/fmed.2024.1418075.


Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries.

Norhammar A, Bodegard J, Eriksson J, Haller H, Linssen G, Banerjee A Diabetes Obes Metab. 2022; 24(7):1277-1287.

PMID: 35322567 PMC: 9321691. DOI: 10.1111/dom.14698.